Patent intelligence · US
US 6248778
Anticholestatic effect of luteolin
Anticholestatic effect of luteolin
Patent details — US 6248778
- Jurisdiction
- US
- Status
- expired
- Grant date
- Jun 19, 2001
- Expiration
- Jun 14, 2021
- Applicant
- Serturner Arzneimittel GmbH
- Claims
- 12
- CPC classes
- A61K, A61K31/352, A61P, A61P1/16
Quick answer
US 6248778 (Anticholestatic effect of luteolin) is held by Serturner Arzneimittel GmbH. Status: expired. Granted Jun 19, 2001. Expires Jun 14, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Serturner Arzneimittel GmbH
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K31/352, A61P, A61P1/16
More from Serturner Arzneimittel GmbH
Related pharmaceutical patents in our USPTO index.
-
US 12310968
Chiral diaryl macrocycles and uses thereof
granted -
US 12252488
HPK1 antagonists and uses thereof
granted -
US 12215105
HPK1 antagonists and uses thereof
granted -
US 12187739
Diaryl macrocycle polymorph
granted -
US 12071442
Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists
granted -
US 11981684
Macrocyclic compounds and uses thereof
granted -
US 11926625
HPK1 antagonists and uses thereof
granted -
US 11802292
Modified orthopoxvirus vectors
granted
Frequently asked questions
What is US patent 6248778?
US 6248778 (Anticholestatic effect of luteolin) is held by Serturner Arzneimittel GmbH. Status: expired. Granted Jun 19, 2001. Expires Jun 14, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6248778?
Serturner Arzneimittel GmbH is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 40 pharmaceutical patents for this assignee.
When does US 6248778 expire?
Our index shows an expiration date of Jun 14, 2021 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.